Tyrvaya®
Varenicline 0.06% · nasal spray
Dry Eye/OSD
Approved uses
Dry eye disease
1 spray in each nostril BID, approximately 12 hours apart; prime with 7 actuations before first use and re-prime with 1 actuation after more than 5 days unused
Tear production rises by week 4 and holds at 12 weeks; dryness symptoms did not improve.
OFF-LABELNot in the FDA label for this product
Perioperative dry eye with LASIK, PRK, or corneal collagen crosslinking, started before surgery
1 spray in each nostril BID beginning 28 days before surgery, continued 84 days after LASIK or PRK and 28 days after crosslinking
3 RCTs · n=101 · all negative
Three small vehicle-controlled trials from one investigator group, randomized per the published reports (LASIK n=40, PRK n=41, crosslinking n=20): no primary endpoint reached statistical significance in any of the three, leaving only directional trends in corneal staining, tear osmolarity, and epithelial closure. The LASIK report concluded that a larger trial is needed.
Contraindications
None.
0.03 mg varenicline per 0.05 mL spray (0.6 mg/mL); 4.2 mL bottles of 60 sprays, in packs of 2 (30-day supply) or 1
Nicotinic acetylcholine receptor agonist delivered intranasally; its efficacy in dry eye disease is believed to be the result of activity at heteromeric sub-type(s) of the nACh receptor, where binding produces agonist activity, activates the trigeminal parasympathetic pathway, and increases production of basal tear film. Partial agonist at α4β2, α4α6β2, α3β4 and α3α5β4 receptors and full agonist at α7; the label states the exact mechanism is unknown.
Warnings & Precautions
Important information: TYRVAYA is for use in the nose.
Common Side Effects
The most common adverse reaction, reported in 82% of patients, was sneezing. Other common adverse reactions reported in more than 5% of patients were cough (16%), throat irritation (13%), and instillation-site (nose) irritation (8%). These rates come from three dry eye disease studies in which 349 patients received at least 1 dose. In ONSET-2, a phase 3 randomized trial, most treatment-emergent adverse events were mild and nonocular (sneezing, cough, throat irritation, and instillation site irritation). Across three clinical trials, 93.5% of subjects receiving varenicline solution nasal spray completed the treatment period.
Pregnancy: No human data. Animal reproduction studies produced no fetal structural abnormalities; maternal toxicity with reduced fetal weights occurred in rabbits at 4864 times the MRHD, and offspring of rats dosed at 1216 times the MRHD showed decreased fertility and increased auditory startle response.
Lactation: No human data on presence in milk, effects on the infant, or milk production; varenicline is present in the milk of lactating rats, but animal data may not reliably predict drug levels in human milk. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for TYRVAYA and any potential adverse effects on the breastfed child.
Safety and efficacy not established in pediatric patients.